Feed CLNN
CL

Clene Inc.

CLNN · NASDAQ

$3.57 -4.03% (-$0.15)
1M -14.80%
Market Cap $51.0M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9
Valuation
0 /100
Expensive
P/S 259.13x
EV/FFO N/A
P/E N/A
Growth
0 /100
Declining
Rev. growth 24.94%
Book val. growth N/A
EPS growth N/A
Profitability
0 /100
Weak
Op. margin 10,304.60%
Gross margin 110.15%
FCF margin 8,103.50%
Quality
0 /100
Poor
Asset turnover 0.01x
ROIC 104.55%
ROA 171.51%
Debt
43 /100
Moderate
Int. coverage -10.15x
Current ratio 3.07x
Debt/Assets N/A
Stability
24 /100
Unstable
EPS volatility 85.50%
Beta 0.95x
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about CLNN
Online

About the company

Clene Inc. (CLNN) is a biotechnology company focusing on the development and commercialization of therapeutic therapies based on nanotechnologies for the treatment of neurodegenerative diseases. The company concentrates on developing therapeutic products that utilize nanocrystalline platforms to support nerve cell recovery and protection from degeneration. Clene Inc. is engaged in addressing diseases like amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. With the growing awareness of the need for neurodegenerative disease treatment, Clene Inc. has the potential for sustained growth. Clene Inc. (CLNN) shares might be an interesting choice for investors seeking involvement in the biotechnology and therapeutic therapies for neurodegenerative diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

Robert Etherington

Employees

78

Headquarters

Salt Lake City

Upcoming events

12 NOV

Earnings

Upcoming earnings report

61d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.